Diagnostic testing, treatment, cost of care, and survival among registered and non-registered patients with myelodysplastic syndromes.

[1]  U. Germing,et al.  Incidence and prevalence of myelodysplastic syndromes: data from the Düsseldorf MDS-registry. , 2011, Leukemia research.

[2]  C. Cogle,et al.  Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries. , 2011, Blood.

[3]  M. Sant,et al.  Sant M, Allemani C, Tereanu C, et al; HAEMACARE Working Group. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood. 2010;116(19):3724-3734 , 2011, Blood.

[4]  F. Berrino,et al.  Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. , 2010, Blood.

[5]  M. Laouri,et al.  Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  D. Steensma.  Myelodysplastic Syndromes : Pathobiology and Clinical Management , 2008 .

[7]  N. Howlader,et al.  Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. , 2008, Blood.

[8]  A. Brett.  Myelodysplastic Syndromes: Incidence and Survival , 2007 .

[9]  P. Greenberg,et al.  Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. , 2006, The New England journal of medicine.

[10]  L. Rimsza,et al.  Efficacy of lenalidomide in myelodysplastic syndromes. , 2005, The New England journal of medicine.

[11]  Deborah Schrag,et al.  Overview of the SEER-Medicare Data: Content, Research Applications, and Generalizability to the United States Elderly Population , 2002, Medical care.

[12]  T Hamblin,et al.  International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.